EA201790531A1 - Применение неридроновой кислоты или ее соли для лечения остеоартроза - Google Patents

Применение неридроновой кислоты или ее соли для лечения остеоартроза

Info

Publication number
EA201790531A1
EA201790531A1 EA201790531A EA201790531A EA201790531A1 EA 201790531 A1 EA201790531 A1 EA 201790531A1 EA 201790531 A EA201790531 A EA 201790531A EA 201790531 A EA201790531 A EA 201790531A EA 201790531 A1 EA201790531 A1 EA 201790531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salt
treatment
acid
nedrid
osteoarthrosis
Prior art date
Application number
EA201790531A
Other languages
English (en)
Other versions
EA033191B1 (ru
Inventor
Варенна Массимо
Original Assignee
Абиоген Фарма Спа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51904075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Абиоген Фарма Спа filed Critical Абиоген Фарма Спа
Publication of EA201790531A1 publication Critical patent/EA201790531A1/ru
Publication of EA033191B1 publication Critical patent/EA033191B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Описано применение неридроновой кислоты или ее соли для лечения остеоартрита. В частности, было показано, что неридроновая кислота или ее соль способны значительно уменьшать выраженность симптомов остеоартрита, таких как боль, ограничения трудоспособности и подвижности, а также уменьшать субхондральные повреждения костного мозга, лежащие в основе возникновения указанных симптомов.
EA201790531A 2014-10-15 2015-10-15 Применение неридроновой кислоты или ее соли для лечения остеоартрита EA033191B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141794 2014-10-15
PCT/IB2015/057929 WO2016059594A1 (en) 2014-10-15 2015-10-15 Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Publications (2)

Publication Number Publication Date
EA201790531A1 true EA201790531A1 (ru) 2017-08-31
EA033191B1 EA033191B1 (ru) 2019-09-30

Family

ID=51904075

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790531A EA033191B1 (ru) 2014-10-15 2015-10-15 Применение неридроновой кислоты или ее соли для лечения остеоартрита

Country Status (32)

Country Link
US (2) US20170209470A1 (ru)
EP (1) EP3206694B1 (ru)
JP (1) JP6839076B2 (ru)
KR (1) KR102591084B1 (ru)
CN (2) CN111939164A (ru)
AU (1) AU2015332060B2 (ru)
BR (1) BR112017006989A2 (ru)
CA (1) CA2963066C (ru)
CL (1) CL2017000915A1 (ru)
CO (1) CO2017003561A2 (ru)
CY (1) CY1123420T1 (ru)
DK (1) DK3206694T3 (ru)
DO (1) DOP2017000096A (ru)
EA (1) EA033191B1 (ru)
EC (1) ECSP17023093A (ru)
ES (1) ES2819186T3 (ru)
HR (1) HRP20201475T1 (ru)
HU (1) HUE052088T2 (ru)
IL (1) IL251421B (ru)
LT (1) LT3206694T (ru)
MX (1) MX2017004826A (ru)
MY (1) MY191481A (ru)
NZ (1) NZ730853A (ru)
PE (1) PE20170699A1 (ru)
PH (1) PH12017500659A1 (ru)
PL (1) PL3206694T3 (ru)
PT (1) PT3206694T (ru)
RS (1) RS60868B1 (ru)
SG (1) SG11201702574XA (ru)
SI (1) SI3206694T1 (ru)
TN (1) TN2017000095A1 (ru)
WO (1) WO2016059594A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190328755A1 (en) * 2018-04-30 2019-10-31 Grunenthal Gmbh Methods of treating complex regional pain syndrome (crps) or symptoms comprising administration of neridronic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
AU2005240107A1 (en) * 2004-05-06 2005-11-17 Merck & Co., Inc. Methods for treating arthritic conditions in dogs
EP1988907A4 (en) * 2006-02-06 2010-04-14 Cypress Bioscience Inc COMPOSITIONS COMPRISING A BISPHOSPHONATE AND AN ANTIFOLATE
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Also Published As

Publication number Publication date
MY191481A (en) 2022-06-28
CY1123420T1 (el) 2021-12-31
CN106794190A (zh) 2017-05-31
BR112017006989A2 (pt) 2018-03-27
CL2017000915A1 (es) 2017-11-10
KR102591084B1 (ko) 2023-10-18
JP2017532333A (ja) 2017-11-02
CN111939164A (zh) 2020-11-17
CA2963066C (en) 2023-12-05
CA2963066A1 (en) 2016-04-21
PL3206694T3 (pl) 2020-12-28
ES2819186T3 (es) 2021-04-15
LT3206694T (lt) 2020-11-25
HUE052088T2 (hu) 2021-04-28
AU2015332060A1 (en) 2017-04-27
MX2017004826A (es) 2018-01-24
RS60868B1 (sr) 2020-11-30
EA033191B1 (ru) 2019-09-30
KR20170066438A (ko) 2017-06-14
PE20170699A1 (es) 2017-06-03
WO2016059594A1 (en) 2016-04-21
HRP20201475T1 (hr) 2020-12-11
SI3206694T1 (sl) 2020-11-30
DOP2017000096A (es) 2017-07-31
US20230233585A1 (en) 2023-07-27
IL251421A0 (en) 2017-05-29
PH12017500659A1 (en) 2017-10-02
ECSP17023093A (es) 2017-06-30
US20170209470A1 (en) 2017-07-27
SG11201702574XA (en) 2017-04-27
NZ730853A (en) 2018-06-29
TN2017000095A1 (en) 2018-07-04
IL251421B (en) 2022-05-01
CO2017003561A2 (es) 2017-09-11
AU2015332060B2 (en) 2018-06-07
EP3206694A1 (en) 2017-08-23
EP3206694B1 (en) 2020-07-08
JP6839076B2 (ja) 2021-03-03
PT3206694T (pt) 2020-09-22
DK3206694T3 (da) 2020-09-21

Similar Documents

Publication Publication Date Title
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201890204A1 (ru) Антибактериальные соединения
HK1247838A1 (zh) 骨質疏鬆症的治療
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EP3294110A4 (en) SYSTEM FOR USE IN THE TREATMENT OF SPINE FRACTURES
EA201591839A1 (ru) Терапевтические пептиды
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201991073A1 (ru) Ингибиторы magl
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201991074A1 (ru) Ингибиторы magl
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201792123A1 (ru) Лечение боли
EP3253886A4 (en) Novel methods for early identification of bone healing ability in injured patients
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EA201691896A1 (ru) Соединения и способы их применения
EP3518951C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF OSTEOPOROSIS AND Fractures
EA201790531A1 (ru) Применение неридроновой кислоты или ее соли для лечения остеоартроза
EA201692051A1 (ru) Арилзамещенные гетероциклилсульфоны
BR112017000359A2 (pt) combinação de pregabalina e meloxicam para o tratamento de dor neuropática
HK1252359A1 (zh) 用於治療疼痛的曲唑酮和加巴噴丁的組合
IL228155A0 (en) Orthopedic implant for the treatment of bone deformities
EA201790537A1 (ru) Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM